Inhibitors of the GPIb-vWF interaction, their preparation and use

US7745443B2 · kind B2 · utility

Assignees

• Sanofi-Aventis Deutschland GMBH · DE
• Ajinomoto Co., Inc.

Inventors

• Otmar Klingler · Rodgau, DE
• Melitta Just · Langen, DE
• Kuniya Sakurai · Kawasaki, JP
• Naoyuki Fukuchi · Yokohama, JP

Key dates

• Filing date: Apr 2, 2007
• Grant date: Jun 29, 2010
• Expiry date: Apr 24, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/12
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds of the formula I,in which R1, R2, A, B, D, E, n, m or o have the meanings indicated below.The compounds of the formula I are valuable pharmacologically active compounds. They are reversible inhibitors of the interaction between the plasma protein von Willebrand factor (vWF) and the blood platelet receptor glycoprotein Ib-IX-V complex (GPIb). They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of atherothrombotic diseases.